| Literature DB >> 26203400 |
Luche Tadesse Ejeta1, Ali Ardalan2, Douglas Paton3.
Abstract
BACKGROUND: Preparedness for disasters and emergencies at individual, community and organizational levels could be more effective tools in mitigating (the growing incidence) of disaster risk and ameliorating their impacts. That is, to play more significant roles in disaster risk reduction (DRR). Preparedness efforts focus on changing human behaviors in ways that reduce people's risk and increase their ability to cope with hazard consequences. While preparedness initiatives have used behavioral theories to facilitate DRR, many theories have been used and little is known about which behavioral theories are more commonly used, where they have been used, and why they have been preferred over alternative behavioral theories. Given that theories differ with respect to the variables used and the relationship between them, a systematic analysis is an essential first step to answering questions about the relative utility of theories and providing a more robust evidence base for preparedness components of DRR strategies. The goal of this systematic review was to search and summarize evidence by assessing the application of behavioral theories to disaster and emergency health preparedness across the world.Entities:
Keywords: Behavior; Emergency Health; Model; Theory; disaster; preparedness
Year: 2015 PMID: 26203400 PMCID: PMC4494855 DOI: 10.1371/currents.dis.31a8995ced321301466db400f1357829
Source DB: PubMed Journal: PLoS Curr ISSN: 2157-3999
| Database | Keywords | Search outcome (number of articles obtained) | Last date of search |
|---|---|---|---|
| PubMed | ((theor* [tiab] OR model* [tiab] AND behavior*[tiab]) OR “health belief model” OR “theory of planned behavior” OR “social cognitive theory” OR “trans theoretical model”) AND (disaster*[tiab] OR emergency* [tiab] OR storm* [tiab] OR cyclone* [tiab] OR typhoon*[tiab] OR hurricane*[tiab] OR tornado*[tiab] OR drought*[tiab] OR earthquake*[tiab] OR flood*[tiab] OR tsunami*[tiab] OR volcano*[tiab] OR “chemical terrorism” OR “biological terrorism” OR “agro terrorism” OR “nuclear terrorism” OR epidemic*[tiab] OR outbreak*[tiab] OR pandem*[tiab]) AND (prepar*[tiab] OR read*[tiab] OR “protective action” OR “adaptive behavior” OR plann*[tiab]) | 229 | November 12, 2014; 10:30 AM |
| Scopus | TITLE-ABS-KEY(theor* OR model* AND Behavior*) OR (“health belief model” OR “theory of planned behavior” OR “social cognitive theory” OR “social network and social supports” OR “trans theoretical model”) AND TITLE-ABS-KEY (disaster* OR emergency* OR storm* OR cyclone OR typhoon* OR hurricane* OR tornado* OR drought* OR earthquake* OR flood* OR tsunami* OR volcano* OR “chemical terrorism” OR “biological terrorism” OR “agro terrorism” OR “nuclear terrorism” OR epidemic*) AND TITLE-ABS-KEY (prepar* OR read* OR “protective action” OR “adaptive behavior” OR plann*). [English language] marked | 1,672 | November 12, 2014; 10:15 AM |
| Mosby’s Index(Nursing Index) | (theory OR model) AND (behavior OR “health belief model” OR “theory of planned behavior” OR “social cognitive theory” OR “social network and social supports” OR “trans theoretical model”) AND (disaster OR emergency OR storm OR cyclone OR typhoon OR hurricane OR tornado OR drought OR earthquake OR flood OR tsunami OR volcano OR “chemical terrorism” OR “biological terrorism” OR “agro terrorism” OR “nuclear terrorism” OR epidemic OR outbreak OR pandemic) AND (preparedness OR readiness OR “protective action” OR “adaptive behavior” OR plan) | 95 | November 12, 2014; 12:30 PM |
| Safetylit | (theory OR model) AND (behavior OR belief OR perception) AND (disaster OR emergency OR hazard) AND (preparedness OR readiness OR plan) | 44 | November 12, 2014;11:30 AM |
OR=Odds Ratio; CI=Confidence Interval; P-values considered significant at <0.05; - result not provided
| Constructs of HBM | Teitler-Regev S, et al. | Taylor P, et al. | Nexøe J, et al. | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Constructs of HBM | OR | 95% CI | P-value | OR | 95% CI | P-value | OR | 95% CI | P-value |
| Susceptibility | 0.23 | - | 0.01 | 0.13 | - | < 0.05 | - | - | - |
| Severity | 0.18 | - | 0.01 | 0.05 | - | >0.05 | 1.11 | 1.07-1.15 | 0.000 |
| Risk | 0.47 | - | 0.04 | - | - | - | - | - | - |
| Self-efficacy | - | - | - | 0.07 | - | >0.05 | - | - | - |
| Benefits | 0.7 | - | 0.43 | 0.27 | - | <0.001 | 1.64 | 1.31-2.03 | 0.000 |
| Barrier | 0.32 | - | 0.01 | 0.04 | - | >0.05 | 0.89 | 0.85-0.94 | 0.000 |
| Cues to action (Health promotion) | 1.3 | - | 0.55 | - | - | - | - | - | - |
OR= Odds Ratio (adjusted for demographic characteristics 19,21); CI= Confidence Interval
| Willingness to respond | Low Threat, High Efficacy | High Threat, Low Efficacy | High Threat, High Efficacy |
|---|---|---|---|
| Willingness to respond | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Barnett DJ et al. | |||
| If required | 16.48 (5.16–52.65) | 2.39 (1.48–3.87) | 41.58 (10.15–170.40) |
| If asked but not required | 5.31 (2.93–9.61) | 1.43 (1.00–2.04) | 8.46 (4.77–15.01) |
| Balicer RD et al. | |||
| If required | 13.09 (7.67 - 22.34) | 1.41 (1.05 - 1.90) | 9.25 (5.94 - 14.40) |
| If asked but not required | 7.12 (4.94 - 10.25) | 1.10 (0.85 - 1.42) | 5.52 (4.03 - 7.56) |
Page numbers refer to the original manuscript
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| TITLE | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 |
| INTRODUCTION | |||
| Rational | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 3 |
| METHODS | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | N/A |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4-5 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4-5 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 6 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | N/A |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | N/A |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | N/A |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 6-7 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 8-17 and Appendix 2 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 8-17 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 8-17 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 8-17 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| DISCUSSION | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 18-20 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 20 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 21 |
| FUNDING | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 21 |